



## **ASX and Media Release**

21 January 2013

### **Dr. Malcolm McColl commences as Chief Executive Officer**

---

I am very pleased to announce that as of today's date, Dr. Malcolm McColl has assumed his role as Chief Executive Officer of Viralytics Ltd.

Dr. McColl has more than twenty years experience with global pharmaceutical and biotech companies across Australia, Europe, USA, Asia, the Middle East and Africa.

He has led international and regional negotiations and due diligence for over fifty research, development, licensing, mergers and acquisitions and other partnering transactions with a focus on oncology.

2013 will be a pivotal year for Viralytics and Dr. McColl's appointment as CEO will be significant for the company's growth and positioning in the field of cancer research.

We welcome him to the Viralytics team.

#### **Paul Hopper Executive Chairman**

Enquiries  
Paul Hopper  
Executive Chairman  
[receptogen@earthlink.net](mailto:receptogen@earthlink.net)  
US Mbl: +1 858 443 5820  
Aust Mbl: 0406 671 515

**About Viralytics Ltd:** Viralytics is listed on the Australian Securities Exchange (ASX code: VLA), Viralytics ADR trades under VRACY on the OTC market in the USA. Viralytics' principal asset is the intellectual property relating to CAVATAK™, an Oncolytic Virus technology. CAVATAK™ is the trade name for Viralytics' proprietary formulation of the Coxsackievirus Type A21 (CVA21). EVATAK™ is the trade name for Viralytics' proprietary formulation of the Echovirus Type 1 (EV1). CVA21 and EV1 are viruses that occur naturally in the community. CVA21 and EV1 attach to the outside of cells using a specific 'receptor' on the cell's surface (like a key fitting a lock). CVA21 uses the receptors, intercellular adhesion molecule-1 (ICAM-1) and/or decay accelerating factor (DAF) to bind and infect target cells. Both of these receptor proteins have been demonstrated to be highly expressed on multiple cancer types including: melanoma, prostate cancer, breast cancer and multiple myeloma. EV1 uses the receptor integrin  $\alpha 2 \beta 1$  (alpha 2 beta 1) to bind and infect target cells. Integrin  $\alpha 2 \beta 1$  (alpha 2 beta 1) has been demonstrated to be highly expressed on multiple cancer types, including: prostate cancer, ovarian cancer.

For personal use only